☰

Welireg (Belzutifan, MK-6482) Clinical Trials (November 2026): 13 Recruiting Interventional Studies of the First-in-Class HIF-2α Inhibitor in Renal Cell Carcinoma, VHL Disease, Pheochromocytoma/Paraganglioma, and Gynecologic Clear-Cell Carcinoma

Last updated: November 5, 2026

Drug profile:

Welireg (belzutifan, MK-6482, formerly PT2977) is the first-in-class small-molecule oral inhibitor of HIF-2α (hypoxia-inducible factor 2 alpha), developed by Merck. It is FDA-approved in 5 settings: VHL disease-associated tumors (RCC, CNS hemangioblastoma, pancreatic NET) since August 13, 2021 (LITESPARK-004); advanced clear-cell RCC after anti-PD-1/PD-L1 and a VEGF-TKI since December 14, 2023 (LITESPARK-005 Phase 3 vs everolimus); advanced pheochromocytoma/paraganglioma (age 12+) since May 14, 2025 (LITESPARK-015); adjuvant clear-cell RCC with pembrolizumab since June 12, 2026 (LITESPARK-022 Phase 3); and in combination with lenvatinib for advanced clear-cell RCC after anti-PD-1/PD-L1 since September 24, 2026 (LITESPARK-011 Phase 3 vs cabozantinib). Dosing: 120 mg orally once daily.

Mechanism of action:

In clear-cell RCC and VHL-associated tumors, biallelic loss of the VHL tumor-suppressor gene prevents degradation of HIF-2α, causing its constitutive stabilization (pseudohypoxia) and transcription of pro-tumor genes including VEGF-A, PDGF, cyclin D1, GLUT1, and erythropoietin. Belzutifan binds an allosteric pocket in the HIF-2α PAS-B domain and blocks its heterodimerization with HIF-1β (ARNT), shutting down the HIF-2 transcriptional program that drives angiogenesis, proliferation, and metabolic reprogramming. Because ccRCC is the paradigm VHL-loss cancer, it is the lead belzutifan indication.

Regulatory status:

FDA-approved in 5 settings: (1) VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic NET not requiring immediate surgery — FDA August 13, 2021, based on LITESPARK-004 (Study 004) Phase 2; (2) advanced RCC after a PD-1/PD-L1 inhibitor and a VEGF-TKI — FDA December 14, 2023, based on LITESPARK-005 Phase 3 vs everolimus (progression-free survival benefit); (3) locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (adults and children 12+) — FDA May 14, 2025, based on LITESPARK-015 (objective response rate 26%); (4) adjuvant clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy, with pembrolizumab — FDA June 12, 2026, based on LITESPARK-022 Phase 3 (disease-free survival HR 0.72 vs pembrolizumab alone; overall survival not statistically significant); (5) with lenvatinib for advanced clear-cell RCC after a PD-1/PD-L1 inhibitor — FDA September 24, 2026, based on LITESPARK-011 Phase 3 vs cabozantinib. The label carries a warning for embryo-fetal toxicity and notes belzutifan can render hormonal contraceptives ineffective. Gynecologic clear-cell carcinoma is investigational (trials ongoing, not FDA-approved).

Why Welireg Matters — In Plain Language

For decades, advanced clear-cell kidney cancer was treated by blocking the downstream consequences of the disease — VEGF-driven blood-vessel growth (with TKIs like sunitinib, cabozantinib, lenvatinib) and immune evasion (with checkpoint inhibitors). Belzutifan is different: it targets the upstream master switch. Nearly all clear-cell RCC starts with loss of the VHL gene, which lets HIF-2α accumulate and switch on the entire pro-tumor program. Belzutifan is the first drug to directly shut off that switch — a genuinely new mechanism (first-in-class) rather than another TKI or antibody.

The VHL story. Belzutifan's first approval (2021) was for people with von Hippel-Lindau disease, an inherited condition where a germline VHL mutation causes tumors across the kidneys, brain/spine (hemangioblastomas), pancreas, and adrenal glands. Before belzutifan, these patients faced repeated surgeries. Belzutifan offered the first systemic option that shrinks VHL-associated tumors across multiple organs at once — a landmark for that community.

The advanced-RCC story and 2026's central question. The 2023 approval extended belzutifan to advanced clear-cell RCC after immunotherapy and VEGF-TKI failure — a setting with few good options. The big question now is whether combining belzutifan with a next-generation TKI can move the HIF-2α approach into earlier lines. That is exactly what the registrational LITESPARK-034 trial (belzutifan + zanzalintinib) tests, with the competing casdatifan + cabozantinib trial as the benchmark. HIF-2α + next-gen TKI is the dominant Phase 3 storyline in advanced ccRCC for 2026.

FDA-Approved Indications

Belzutifan has 5 active FDA approvals, all anchored in VHL / HIF-2α pseudohypoxia biology — including two 2026 combination approvals in RCC (adjuvant with pembrolizumab in June; with lenvatinib in September).

1. VHL Disease-Associated RCC, CNS Hemangioblastoma, or Pancreatic NET (LITESPARK-004)

Pivotal trial: LITESPARK-004 / Study 004 Phase 2 · FDA: August 13, 2021 · Setting: Adults with von Hippel-Lindau (VHL) disease requiring therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery · Significance: first systemic therapy for VHL-associated tumors — durable responses across kidney, CNS, and pancreatic lesions simultaneously, reducing the need for repeated organ-sparing surgeries.

2. Advanced RCC after Anti-PD-1/PD-L1 and a VEGF-TKI (LITESPARK-005)

Pivotal trial: LITESPARK-005 Phase 3 vs everolimus · FDA: December 14, 2023 · Setting: Adults with advanced renal cell carcinoma following a programmed death receptor-1 (PD-1) or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) · Endpoint: progression-free survival benefit vs everolimus · Significance: gives the heavily-pretreated post-IO/post-TKI ccRCC population a mechanistically-novel oral option distinct from yet another VEGF-TKI.

3. Advanced Clear-Cell RCC after Anti-PD-1/PD-L1 — Belzutifan + Lenvatinib (LITESPARK-011)

Pivotal trial: LITESPARK-011 Phase 3 (NCT04586231, n=747, active, not recruiting) vs cabozantinib · FDA: September 24, 2026 · Setting: Adults with advanced renal cell carcinoma with a clear cell component following a PD-1 or PD-L1 inhibitor · Results: median PFS 14.6 vs 10.6 months (HR 0.74); objective response rate 53% vs 40%; overall survival 33.7 vs 28.6 months, not statistically significant (HR 0.85) · Dose: belzutifan 120 mg + lenvatinib 20 mg once daily · Significance: moves belzutifan earlier — to the first line after immunotherapy, rather than only after both IO and a VEGF-TKI — and beats the most-used second-line standard.

4. Advanced Pheochromocytoma or Paraganglioma (LITESPARK-015)

Pivotal trial: LITESPARK-015 Phase 2 (NCT04924075, cohort A1, n=72) · FDA: May 14, 2025 · Setting: Adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma · Results: objective response rate 26%; median duration of response 20.4 months · Significance: first oral therapy approved for PPGL.

5. Adjuvant Clear-Cell RCC after Nephrectomy — Belzutifan + Pembrolizumab (LITESPARK-022)

Pivotal trial: LITESPARK-022 Phase 3 (n=1,841) vs placebo + pembrolizumab · FDA: June 12, 2026 · Setting: Adults with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or nephrectomy and resection of metastatic lesions · Results: disease-free survival HR 0.72 (95% CI 0.59–0.87); overall survival not statistically significant at the analysis · Duration: belzutifan 120 mg daily with pembrolizumab for up to 54 weeks · Significance: first HIF-2α inhibitor approval in the curative-intent (adjuvant) setting.

★ First-in-Class: Targeting the Upstream Driver, Not the Downstream Effects

Every prior advanced-RCC systemic therapy targets a downstream consequence of VHL loss — VEGF-driven angiogenesis (TKIs, bevacizumab), mTOR signaling (everolimus), or immune evasion (checkpoint inhibitors). Belzutifan is the first and only approved drug that inhibits HIF-2α directly, the transcription factor at the top of the ccRCC cascade. This is why it retains activity after TKIs and IO have failed: it acts on a different node.

The trade-off is an on-target class effect: because HIF-2α normally drives erythropoietin (the hormone that tells the marrow to make red cells), inhibiting it causes anemia in the large majority of patients — the most predictable belzutifan toxicity and a direct readout that the drug is hitting its target. Hypoxia is the other on-target effect. These distinguish belzutifan sharply from the fatigue/hand-foot/hypertension profile of the multikinase TKIs.

Recruiting Welireg / Belzutifan Trials

Curated set of recruiting interventional belzutifan / Welireg / MK-6482 trials in the ClinTrialFinder corpus as of November 2026 (13 recruiting interventional trials testing belzutifan on ClinicalTrials.gov — intervention search "belzutifan OR MK-6482", recruiting + interventional returns 15, minus a PET-imaging study and a drug-screening microdevice study where belzutifan is not the study treatment; checked November 5, 2026), grouped by setting and ordered by phase.

Phase 3 — Advanced RCC: Belzutifan + Zanzalintinib (LITESPARK)

Competing HIF-2α benchmark: NCT07011719 tests casdatifan (AB521) + cabozantinib vs placebo + cabozantinib in advanced ccRCC (Phase 3) — the head-to-head reference for the HIF-2α + TKI approach against belzutifan's LITESPARK-034. For the cross-cancer TKI class context (cabozantinib, zanzalintinib, lenvatinib), see the Multikinase Inhibitors hub.

Phase 2 — Localized, Perioperative & Surveillance RCC

VHL Disease & Pheochromocytoma/Paraganglioma

Emerging Non-RCC HIF-2-Driven & Combination Approaches

Mechanism: First-in-Class HIF-2α Transcription-Factor Inhibitor

Belzutifan binds an allosteric pocket within the PAS-B domain of HIF-2α and prevents it from heterodimerizing with its obligate partner HIF-1β (ARNT). Without that dimer, HIF-2α cannot bind hypoxia-response elements in DNA, so the downstream program — VEGF-A (angiogenesis), PDGF, cyclin D1 (proliferation), GLUT1 (glucose uptake), and erythropoietin (red-cell production) — is switched off. In VHL-deficient clear-cell RCC, HIF-2α is the linchpin oncogenic driver, which is why a transcription-factor inhibitor — historically considered “undruggable” — produces meaningful anti-tumor activity here.

Side Effects and Practical Considerations

On-Target Class Effects: Anemia & Hypoxia

Anemia occurs in the large majority of patients (~76-90%) and is a direct, expected consequence of HIF-2α inhibition suppressing erythropoietin — it is essentially a pharmacodynamic readout that the drug is working. Hypoxia (~10-20%) can be clinically significant and is monitored with pulse oximetry. Both are managed with dose modification and supportive care (transfusion/ESA for anemia; oxygen for hypoxia). These on-target effects distinguish belzutifan from the hypertension / hand-foot / fatigue profile of the multikinase TKIs.

Other common adverse events include fatigue, nausea, and headache. The FDA label carries a warning for embryo-fetal toxicity, and belzutifan can render hormonal contraceptives ineffective — patients of reproductive potential need non-hormonal contraception counseling. Belzutifan is dosed 120 mg orally once daily.

Sequencing: Where Does Belzutifan Fit?

In VHL disease, belzutifan is a first-line systemic option for associated RCC/hemangioblastoma/pNET not needing immediate surgery. In resected clear-cell RCC at intermediate-high or high risk of recurrence, belzutifan + pembrolizumab is an FDA-approved adjuvant option (LITESPARK-022, June 2026). In advanced PPGL, it is FDA-approved (LITESPARK-015, May 2025). In sporadic advanced clear-cell RCC, the label positions belzutifan in two places: with lenvatinib right after a PD-1/PD-L1 inhibitor (LITESPARK-011, September 2026 — typically second line; it beat cabozantinib on progression-free survival but not, statistically, on overall survival), and as monotherapy after a PD-1/PD-L1 inhibitor and a VEGF-TKI (2L+/post-IO+TKI). The LITESPARK-034 belzutifan + zanzalintinib and casdatifan + cabozantinib Phase 3 trials are testing whether HIF-2α + next-gen TKI combinations can move HIF-2α inhibition into earlier lines. For the disease-level view of where belzutifan sits among all RCC options, see the renal cell carcinoma trials page.

Frequently Asked Questions

What is Welireg (belzutifan) and how does it work?

Welireg (belzutifan, MK-6482) is the first-in-class oral HIF-2α inhibitor from Merck. In clear-cell RCC and VHL-associated tumors, loss of the VHL gene stabilizes the transcription factor HIF-2α (pseudohypoxia), which drives VEGF, PDGF, and other pro-tumor genes. Belzutifan binds HIF-2α and blocks it from partnering with HIF-1β (ARNT), shutting down that program. Dose: 120 mg once daily by mouth.

What is LITESPARK-034 and is it recruiting?

LITESPARK-034 (LS-034 / MK-6482-034, NCT07489495) is a recruiting Phase 3 trial of belzutifan + zanzalintinib (a next-generation VEGFR/MET/AXL TKI) in renal cell carcinoma — the registrational HIF-2α + next-gen TKI doublet. It is part of Merck's LITESPARK program alongside the LITESPARK-043 extension (NCT07405164) and a recurrent-after-adjuvant trial (NCT07227402). See the full belzutifan recruiting list above.

What is Welireg FDA-approved for?

Five approvals: (1) Aug 13, 2021 — VHL disease-associated RCC, CNS hemangioblastomas, or pancreatic NET not requiring immediate surgery (LITESPARK-004); (2) Dec 14, 2023 — advanced RCC after a PD-1/PD-L1 inhibitor and a VEGF-TKI (LITESPARK-005 Phase 3 vs everolimus); (3) May 14, 2025 — locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, age 12+ (LITESPARK-015; objective response rate 26%); (4) Jun 12, 2026 — with pembrolizumab as adjuvant treatment for clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy (LITESPARK-022 Phase 3; disease-free survival HR 0.72); (5) Sep 24, 2026 — with lenvatinib for advanced clear-cell RCC after a PD-1/PD-L1 inhibitor (LITESPARK-011 Phase 3 vs cabozantinib; median PFS 14.6 vs 10.6 months, HR 0.74; overall survival not statistically significant). Gynecologic clear-cell carcinoma is investigational (trials ongoing).

What are the main side effects of belzutifan?

The two defining effects are on-target: anemia (very common, ~76-90%, because HIF-2α drives erythropoietin) and hypoxia (~10-20%, monitored with pulse oximetry). Fatigue, nausea, and headache are also common. The label warns of embryo-fetal toxicity and notes belzutifan can make hormonal contraceptives ineffective.

How does belzutifan compare to casdatifan?

Belzutifan (Welireg) is the FDA-approved first-in-class HIF-2α inhibitor. Casdatifan (AB521) is an investigational HIF-2α inhibitor in Phase 3 with cabozantinib (NCT07011719). Both test the HIF-2α + next-gen TKI strategy in advanced ccRCC — belzutifan + zanzalintinib (LITESPARK-034) vs casdatifan + cabozantinib. This is the central Phase 3 storyline in advanced ccRCC for 2026.

Find belzutifan / HIF-2α and RCC trials matched to your situation

Choose your diagnosis for trial matching